S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

NRIX Nurix Therapeutics Inc

20.00

0.04 (0.20%)

25 Jan 2025 - Closed

Delayed by 15 minutes

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Nurix Therapeutics (NASDAQ:NRIX)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Nurix Therapeutics Charts.

Nurix Therapeutics (NASDAQ:NRIX)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Nurix Therapeutics Charts.

Nurix Therapeutics Inc News

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer
Wednesday 22 January 2025 (3 days ago) • GlobeNewswire Inc.

Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases
Monday 13 January 2025 (2 weeks ago) • GlobeNewswire Inc.

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Saturday 11 January 2025 (2 weeks ago) • Edgar (US Regulatory)

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Monday 6 January 2025 (3 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Friday 3 January 2025 (3 weeks ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Friday 3 January 2025 (3 weeks ago) • Edgar (US Regulatory)

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
Thursday 19 December 2024 (1 month ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 10 December 2024 (2 months ago) • Edgar (US Regulatory)

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting
Tuesday 10 December 2024 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 3 December 2024 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Tuesday 3 December 2024 (2 months ago) • Edgar (US Regulatory)

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting
Monday 2 December 2024 (2 months ago) • GlobeNewswire Inc.

More Nurix Therapeutics Inc News Articles

Newcrest Mining

Australia And New Zealan...

National Australia Bank

AUD vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions